CD276 and renal cell carcinoma: Furthermore, B7-H3 silencing enhanced sensitivity to the tyrosine kinase inhibitor axitinib in RCC cell lines, indicating that targeting B7-H3 could yield synergistic effects when combined with established therapies [57].